Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) have received a consensus recommendation of “Hold” from the thirteen ratings firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, five have assigned a hold rating and two have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $35.96.

FMS has been the topic of several research analyst reports. JPMorgan Chase & Co. cut their price objective on Fresenius Medical Care AG & Co. KGaA from €23.00 ($24.73) to €17.10 ($18.39) in a report on Tuesday, November 1st. Jefferies Financial Group downgraded Fresenius Medical Care AG & Co. KGaA from a “buy” rating to an “underperform” rating and cut their price target for the stock from $14.00 to $11.70 in a report on Monday, January 2nd. Berenberg Bank cut their price target on Fresenius Medical Care AG & Co. KGaA from €57.95 ($62.31) to €51.80 ($55.70) in a report on Wednesday, October 26th. StockNews.com downgraded Fresenius Medical Care AG & Co. KGaA from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 28th. Finally, Deutsche Bank Aktiengesellschaft cut their price target on Fresenius Medical Care AG & Co. KGaA from €24.00 ($25.81) to €22.00 ($23.66) and set a “sell” rating on the stock in a report on Thursday, November 3rd.

Fresenius Medical Care AG & Co. KGaA Price Performance

FMS stock opened at $17.83 on Friday. The company has a current ratio of 1.34, a quick ratio of 0.96 and a debt-to-equity ratio of 0.48. The company has a market capitalization of $10.45 billion, a PE ratio of 12.65 and a beta of 1.00. Fresenius Medical Care AG & Co. KGaA has a 12-month low of $12.78 and a 12-month high of $35.04. The business’s fifty day moving average price is $15.86 and its 200 day moving average price is $17.05.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMSGet Rating) last posted its quarterly earnings data on Sunday, October 30th. The company reported $0.40 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.37 by $0.03. The firm had revenue of $5.14 billion for the quarter, compared to the consensus estimate of $4.60 billion. Fresenius Medical Care AG & Co. KGaA had a return on equity of 6.03% and a net margin of 4.01%. On average, sell-side analysts anticipate that Fresenius Medical Care AG & Co. KGaA will post 1.43 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in FMS. Wipfli Financial Advisors LLC acquired a new position in shares of Fresenius Medical Care AG & Co. KGaA during the 3rd quarter worth about $25,000. CWM LLC boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 82.0% during the 3rd quarter. CWM LLC now owns 1,753 shares of the company’s stock worth $25,000 after acquiring an additional 790 shares in the last quarter. Quadrant Capital Group LLC boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 283.3% during the 3rd quarter. Quadrant Capital Group LLC now owns 4,446 shares of the company’s stock worth $62,000 after acquiring an additional 3,286 shares in the last quarter. Creative Financial Designs Inc. ADV boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 98.0% during the 2nd quarter. Creative Financial Designs Inc. ADV now owns 3,960 shares of the company’s stock worth $99,000 after acquiring an additional 1,960 shares in the last quarter. Finally, IFP Advisors Inc boosted its position in shares of Fresenius Medical Care AG & Co. KGaA by 1,948.1% during the 3rd quarter. IFP Advisors Inc now owns 1,618 shares of the company’s stock worth $120,000 after acquiring an additional 1,539 shares in the last quarter. 5.56% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care AG & Co. KGaA Company Profile

(Get Rating)

Fresenius Medical Care AG & Co KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.

See Also

Analyst Recommendations for Fresenius Medical Care AG & Co. KGaA (NYSE:FMS)

Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.